---
title: PsyPal; Psilocybin Therapy for Psychological Distress in Palliative Patients
euct_id: 2023-510488-36-01
phase: Phase 4
status: Recruiting
sponsor: Universitair Medisch Centrum Groningen
canonical_url: "https://parkinsonspathways.com/trials/eu/2023-510488-36-01"
eu_clinical_trials_register: "https://euclinicaltrials.eu/ctis-public/view/2023-510488-36-01"
ctis_last_updated: "2026-05-05T03:33:04.581485401"
source: EU Clinical Trials Information System (CTIS)
---
# PsyPal; Psilocybin Therapy for Psychological Distress in Palliative Patients

**EU CT Number:** [2023-510488-36-01](https://euclinicaltrials.eu/ctis-public/view/2023-510488-36-01)

## Key Facts

- **Phase:** Phase 4
- **Status:** Recruiting
- **Sponsor:** Universitair Medisch Centrum Groningen
- **Start Date:** 2025-01-01
- **Completion Date:** 2027-01-01
- **Conditions:** Chronic obstructive pulmonary disease (COPD), amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), and atypical Parkinson disorder (APD), particularly multiple system atrophy (MSA), progressive supranuclear palsy (PSP), and corticobasal syndrome (CBS).
- **Interventions:** Psilocybin capsules 15 mg, Psilocybin capsules 25 mg, Psilocybin capsules 1 mg

## Member States

Trial is authorized in 4 member states: Czechia, Denmark, Netherlands, Portugal.

## Sites (4)

- Universitair Medisch Centrum Groningen, Groningen, Netherlands
- Narodni Ustav Dusevniho Zdravi, Klecany, Czechia
- Champalimaud Clinical Centre, Lisbon, Portugal
- Region Hovedstaden, Copenhagen Nv, Denmark

## Eligibility (CTIS)

- **Minimum age:** 18 Years
- **Sex:** ALL

```
Condition: Chronic obstructive pulmonary disease (COPD), amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), and atypical Parkinson disorder (APD), particularly multiple system atrophy (MSA), progressive supranuclear palsy (PSP), and corticobasal syndrome (CBS).
Age groups: elderly 65+, adults 18-64
Sex: male, female
```

---

*Canonical: https://parkinsonspathways.com/trials/eu/2023-510488-36-01*  
*HTML version: https://parkinsonspathways.com/trials/eu/2023-510488-36-01*  
*Source data: https://euclinicaltrials.eu/ctis-public/view/2023-510488-36-01*